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Observing the basic requirements for prescribing immunomodu-
lating therapy, i.e., therapy well grounded, differentiated, purposeful 
and individualizad, we set ourselvers a goal to make an attempt to 
assess the clinical effectiveness of some known and used in this 
country immunostimulating medicines and these medicines applied 
to patients with frequent chronic nonspecific pulmonary diseases. 
For the period 1983-1991 in the Clinic of Pulmology, Medical Univer-
sity, Varna, 197 patients with frequent pushes of chronic nonspecific 
pulmonary diseases (CNPD) and protracted course of acute bacteri-
al pneumonia and signs for immunodeficiency were checked up. 
Their immunodeficiency was determined on the basis of the results 
obtained from the examination of the following indexes: phagocyte 
activity of polymorphic nuclear leukocytes and alveolar macro-
phages, lysozyme in serum and bronchial secretion, protease inhibi-
tors, complement, Ig G,A,M, including specific antibodies in serum 
and bronchial secretion, circulating immune complexes, E-rosette-
forming cells, intradermal test with purified protein derivative of 
tuberculine, candidine, trichophytin as a test for proving the cellular 
mediated immune deficiency. All the patients received immunomodu-
lating medicines in correspondence with their immunity breaches: 
I. DECARIS (Levamisol) given to 63 patients by the following 
way: 2,5 mg/kg daily (on the average 150 mg) during 3-5 days and 
then one tablet (150 mg) weekly for the following month. II. GAMMA 
A - new Bulgarian medicine (enriched with IgA gamma globulin) for 
correction of IgA and IgG-deficit was given to patients with signs of 
deficiency of antibody synthesis. 17 of them received 0,3-0,5 ml/kg, 
followed by a dose of 0,3-0,55 ml/kg once in fortnight under observ-
ance of their serum immunoglobulin levels. In some cases the bron-
chial secretion was under control during the period of treatment. 
IN. ANTISTENOCARDIN (Dipiridamol) - interferon inductor was 
given to 91 patients with CNPD. The dose prescribed was 100 mg 
once a week for 3 months. 19 patients with frequent recurrences of 
CNPD and virus infections inhaled the newly invented Bulgarian leu-
kocyte interferon 3-5 times - 50000 U each time. IV. RESPIVAX - new 
Bulgarian polymicrobial immunomodulator that proved to have 
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stimulating effect on antibody synthesis, phagocytosis and cellular 
immunity was applied to 62 patients with signs of dysfunction of the 
phagocytosis, humoral and cellular immunity in following dosage: 
basic course 1 tablet (50 mg) every morning for 30 days; after that 
10 days monthly every morning 1 tablet (50 mg) for at least 3 months. 
V. ISOPRENASIN - immunomodulator was also included in the com-
plex therapy of patients with non-bacterial pheumonia and unusually 
complicated course and with signs of cellular-mediated immunity 
deficiency. The dose was 50 mg/kg during a period of 7-10 days. To 
assess the effect of the treatment the following criteria were used -
clinical and immunologic: correction of the deficiency and the dyss-
function of a particular section of the immunity system. Our results 
are demonstrated on table 1. 
Table 1. Clinical effectiveness of the complex therapy combined 
with immunomodulaters and applied to patients with frequent recur-















Decaris 63 41 5,07 40 63,5 28 44,44 
Respivax 62 41 66,02 51 82,25 19 30,60 
GammaA 17 5 29,41 7 41,17 5 29,41 
Antisteno- 19 12 63,20 3 15,78 3 15,78 
cardin 
Levamisol (Decaris) and Respivax proved to have good antire-
current effect for two thirds of the treated patients. Dipiridamol 
proved significant antirecurrent effect in patients with positive re-
sponse to interferon after induction with it. Gamma A proved small 
antirecurrent effect and that is why we recommend its usage as an 
immunosubstitution in the complex therapy. Apart from the favour-
able clinical effect and practically lack of side effects, usage of vari-
ous immunomodulators improved some immunologic index without 
normalization. 
